“Introducing Ashley Tarasiewicz: A New Member of the Pharmaverse Council”

Hello pharmaverse community!

I’m thrilled to announce that Ashley Tarasiewicz will be taking over the Atorus seat from me on the Pharmaverse council.

Ashley has been a contributor to the pharmaverse since the early days of its inception, contributing to packages such as {Tplyr} , {pharmaRTF}, and {metacore} . One of Ashley’s biggest strengths is being a voice of the user, calling on her history working through clinical reporting and submissions. In the time since Ashley joined Atorus, she built Atorus Academy to help with the up-skilling of SAS programmers to learn R. Ashley has now transitioned to the product owner OpenVal, a validated R distribution.

It was a no-brainer for me to have Ashley take over my council seat. For me personally, Ashley is an individual that I’ve leaned on since the very beginning of my career. As a sounding board and trusted confidant, having her at Atorus has been critical to our success. As such, I’m confident that her voice in the pharmaverse council will continue to help steer the community and drive progress for the industry overall.

Welcome, Ashley!

@online{stackhouse2025,
  author = {Stackhouse, Mike},
  title = {Welcome, {Ashley} {Tarasiewicz}},
  date = {2025-04-16},
  url = {https://pharmaverse.github.io/blog/posts/2025-04-16_welcome,__a.../welcome,__ashley__tarasiewicz.html},
  langid = {en}
}

Continue reading: Welcome, Ashley Tarasiewicz

Introduction

In recent developments, Ashley Tarasiewicz has been recruited by Atorus to head the company’s seat at the pharmaverse council. This comes after several years of significant contributions to the pharmaverse by Ashley, through her innovations such as Tplyr, PharmaRTF and metacore. As Ashley takes up a new role as a product owner of OpenVal, there is much to anticipate regarding the direction of the company under her stewardship. This article aims to evaluate the potential implications and future developments that may arise from this new introduction.

Implications and Future Developments

Enhancements in Clinical Reporting and Submission

Given Ashley’s background in clinical reporting and submissions, one of the potential long-term implications is that Atorus may now streamline its reporting, analysis and submission process. This would lead to efficient data management and potentially faster drug delivery to the market.

Professional Development Opportunities

With the establishment of Atorus Academy by Ashley, a platform for the up-skilling of SAS programmers has been created. In the long run, this could lead to the up-skilling of industry professionals to learn R, consequently pushing the boundaries of industry knowledge and technical ability.

Product Expansion

Ashley’s new role as the product owner of OpenVal might be a sign of potential new innovative products or improvements to the existing ones. OpenVal, as a validated R distribution, may be further developed under Ashley’s influence to include more comprehensive statistical and graphical techniques for improved data analyses.

Actionable Recommendations

1. Professional Growth: With the opportunity provided by Atorus Academy to learn R, industry professionals are encouraged to take this opportunity to enhance their skills. This will not only provide an individual advantage but also elevate the standard of the industry.
2. Market Watch: Potential competitors and investors should monitor the developments at Atorus under Ashley’s watch. With her track record, innovatively new products can be expected.
3. Industry Collaboration: Considering Ashley’s voice in the pharmaverse council, there should be more engagement with her views by other council members and the industry. This would involve keen tracking of her propositions and developing suitable policies and responses.

Conclusion

In conclusion, Ashley Tarasiewicz’s assumption of Atorus’ pharmaverse council seat is a significant development that holds potential for positive change in the pharmaceutical programming landscape. Professionals, competitors, investors and market watchers should brace themselves for industry forwarding initiatives.

Read the original article